Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a Booster

Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a Booster

  • CEPI commits up to an additional US$36.9 million for a total investment of up to $397.4 million to support the development of Clover’s COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum)
  • CEPI funding supports development of SCB-2019 (CpG 1018/Alum) for primary vaccination across all age groups (pediatric, adolescent, adults, and elderly) and development as a potential booster

CHENGDU, China and OSLO, Norway, Nov. 18, 2021 (GLOBE NEWSWIRE) -- , a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates, and , the Coalition for Epidemic Preparedness Innovations, today announced that CEPI will provide up to an additional US$36.9 million in funding to support continued development of SCB-2019 (CpG 1018/Alum) through licensure. This brings CEPI’s total potential funding in SCB-2019 (CpG 1018/Alum) up to US$397.4 million, which represents one of CEPI’s largest investments in a COVID-19 vaccine manufacturer to date. Previous CEPI funding has supported preclinical and clinical testing of the vaccine, in addition to scaling up the manufacturing process. Pending WHO Emergency Use Listing (EUL), Clover will supply up to 414 million doses of the vaccine to the COVAX Facility for equitable distribution.

Clover is utilizing the funding from CEPI to develop SCB-2019 (CpG 1018/Alum) as a primary vaccination for all age groups (pediatric, adolescent, adults and elderly) and as a potential booster for previously-infected individuals and populations that have received SCB-2019 (CpG 1018/Alum) for the primary vaccination (homologous booster). In September 2021, Clover announced SPECTRA, a global pivotal phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of SCB-2019 (CpG 1018/Alum) met the primary and secondary endpoints and that a single dose of SCB-2019 (CpG 1018/Alum) in individuals who had previously been infected by SARS-CoV-2 induced a rapid and strong boosting effect on neutralizing antibody titers1. Evaluation of SCB-2019 (CpG 1018/Alum) as a homologous booster will be conducted as an expansion arm of SPECTRA and initiate in the near-term. Clover is also in the process of planning multiple heterologous booster studies with SCB-2019 (CpG 1018/Alum).

“Clover appreciates the continued partnership with CEPI and their support for developing SCB-2019 (CpG 1018/Alum) as a potential COVID-19 booster vaccine. We believe that SCB-2019 (CpG 1018/Alum) is well-positioned to be evaluated as a universal COVID-19 booster vaccine, given the significant efficacy against variants as well as the favorable safety profile demonstrated in the Phase 2/3 SPECTRA trial. If successful, SCB-2019 (CpG 1018/Alum) could be an important tool to provide continued protection against COVID-19 for those most in need globally,” said Joshua Liang, CEO of Clover Biopharmaceuticals.

Dr. Richard Hatchett, CEO of CEPI noted, “While multiple safe and effective COVID-19 vaccines are now available we know that COVID-19 is here to stay, so further R&D is needed to inform vaccination strategies that will help control the virus in the long-term. I’m pleased to further expand CEPI’s R&D partnership with Clover which will maximize the potential impact of this vaccine as we seek to protect those most at risk from COVID-19, wherever they are in the world.”

About SCB-2019 (CpG 1018/Alum)

SCB-2019 (CpG 1018/Alum), Clover’s COVID-19 vaccine candidate, is anticipated to potentially be one of the first protein-based COVID-19 vaccines commercialized globally through the COVAX Facility. Employing the Trimer-Tag™ technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer™) based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2.

For more information, please visit our website: and follow the company on .

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19 CEPI’s work focused on developing vaccines against Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus - it has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).

During the current pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms previously developed by CEPI’s partners prior to the emergence of COVID-19 as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation to these vaccines worldwide through COVAX.

CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a universal vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at .

Follow our for the latest updates. Follow us on  and .

About the COVAX Facility 

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. 

Forward-looking Statements (relating to Clover)

This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used in this [document], the words “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “going forward,” “intend,” “may,” “might,” “ought to,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.

Clover Biopharmaceuticals:

Cindy Min

SVP, Public Affairs

Naomi Eichenbaum

VP, Investor Relations









To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com




三叶草生物新冠候选疫苗2/3期临床试验“SPECTRA”保护效力最终数据在《柳叶刀》发表 中国成都, Jan. 21, 2022 (GLOBE NEWSWIRE) -- 致力于开发新型疫苗和生物疗法的临床试验阶段的全球生物制药公司—(以下简称“三叶草生物”;香港联交所股票代码:02197.HK)今天宣布,其旨在评估新冠候选疫苗SCB-2019(CpG 1018/铝佐剂)有效性、安全性和免疫原性的2/3期临床试验(“SPECTRA”)的最终保护效力数据发表于同行评审期刊《柳叶刀》。请点击此处查阅题为《重组蛋白亚单位新冠候选疫苗SCB-2019的保护效力 - 一项多中心、双盲、随机、安慰剂对照2期和3期临床试验》的。 “SPECTRA”临床试验数据显示,三叶草生物新冠候选疫苗SCB-2019(CpG 1018/铝佐剂)成功达到临床保护效力的主要终点和次要终点,对预防任何毒株引起的重度和需住院治疗的新冠肺炎(COVID-19)保护效力为100%。此外,SCB-2019(CpG 1018/铝佐剂)还表现出良好的安全性,疫苗组与安慰剂组相比,全身不良事件或严重不良事件无显著差异。 三叶草生物疫苗科学委员会主席Ralf Clemens博士表示:“我们非常高兴看到三叶草生物新冠候选疫苗的关键性2/3期临床试验‘SPECTRA’的结果能够通过同行审阅并在《柳叶刀》上发表。‘SPECT...


Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Publi...

Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet CHENGDU, China, Jan. 21, 2022 (GLOBE NEWSWIRE) -- . (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final efficacy data from SPECTRA, a global Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet. The paper, ‘Efficacy of the adjuvanted subunit protein Covi...


三叶草生物“SPECTRA”项目首批受试者 完成新冠候选疫苗同源加强针接种

三叶草生物“SPECTRA”项目首批受试者 完成新冠候选疫苗同源加强针接种 调整后的“SPECTRA”项目将评估SCB-2019(CpG 1018/铝佐剂)作为同源加强针的效力,约4000名成年受试者将接种评估SCB-2019(CpG 1018/铝佐剂)作为同源加强针及其针对青少年的免疫原性和安全性的初始数据预计于2022年上半年发布 中国成都, Jan. 05, 2022 (GLOBE NEWSWIRE) -- 致力于开发新型疫苗和生物疗法的临床试验阶段的全球生物制药公司—(以下简称“三叶草生物”;香港联交所股票代码:02197.HK)今天宣布,首批受试者已完成新冠候选疫苗SCB-2019(CpG 1018/铝佐剂)同源加强针的接种。这些受试者在全球2/3期临床试验“SPECTRA”中已接种SCB-2019(CpG 1018/铝佐剂)进行基础免疫。2021年9月,三叶草生物公布了“SPECTRA”项目的SCB-2019(CpG 1018/铝佐剂)最终有效性数据,该项目仍在开展中,将继续获取更多的免疫原性和安全性数据。 这项双盲、随机及对照研究旨在评估两种SCB-2019剂量配方(全剂量: 30微克抗原加 CpG 1018/铝佐剂;半剂量:15微克抗原加CpG 1018/铝佐剂)作为同源加强针的免疫原性和安全性,约4000名成年受试者将完成加强针接种,这些受试...


Clover Doses First Participants with Homologous Booster Dose of COVID-...

Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA SPECTRA has been amended to evaluate SCB-2019 (CpG 1018/Alum) as a homologous booster in approximately 4,000 adult participants previously vaccinated with SCB-2019 (CpG 1018/Alum)Initial immunogenicity and safety data for SCB-2019 (CpG 1018/Alum) as a homologous booster and for adolescents are anticipated in the first half of 2022 CHENGDU, China, Jan. 05, 2022 (GLOBE NEWSWIRE) -- , a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates...



三叶草生物上海研发中心在张江高科技园区正式动工 三叶草生物上海研发中心将支持其基于Trimer-Tag™(蛋白质三聚体化)及其他技术平台开展的新型疫苗和创新疗法的临床前开发、生产工艺开发以及中试生产等,并计划在该地区招聘数百名新员工。 中国成都, Jan. 05, 2022 (GLOBE NEWSWIRE) -- 致力于开发新型疫苗和生物疗法的临床试验阶段的全球生物制药公司—(以下简称“三叶草生物”;香港联交所股票代码:02197.HK)今日宣布,其位于上海张江生物医药科技产业基地的三叶草生物上海研发中心已正式动工。张江生物医药科技产业基地位于上海市张江高科技园区,被誉为“张江药谷”,是中国顶尖的生物医药高科技产业集群之一,汇聚超过一千家创新生物技术和生物制药公司。 三叶草生物上海研发中心规划占地超两万五千平方米,将建成一个拥有全新临床前研发实验室、生产工艺开发实验室和GMP中试生产车间的具国际顶尖水准的研发基地。研发设施的建设预计于2022年第二季度完成,整个研发中心计划于2022年下半年落成。三叶草生物计划在当地招聘数百名新员工,以扩展三叶草生物现有的研发能力,加速多个创新候选产品的开发。 三叶草生物首席执行官梁果表示:“三叶草生物在上海新建的研发中心,将进一步扩展我们的研发能力,加速开发创新管线产品。未来,我们还计划在全球范围内布局更多的研发中心,以推进创新...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch